US Stock Movement: Oruka Therapeutics surged on October 20; BTIG reiterated Buy rating and released ORKA-001 clinical data

Bitget异动解读2026/10/20 18:15

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oruka Therapeutics October 20 Surge Analysis

Keywords: BTIG reaffirms Buy, ORKA-001 clinical data

1. On October 19, BTIG reaffirmed its "Buy" rating on Oruka Therapeutics and maintained a target price of $151; analysts referenced the clinical data of ORKA-001.

2. On September 23, the company announced the week 28 results of the EVERLAST-A Phase IIa trial: the PASI 100 response rate in the ORKA-001 group was 71.4%, and the PASI 90 response rate was 87.3%, with no additional dosing after week 4.

(Disclaimer: This content is generated by AI technology by summarizing publicly available information and is for reference only. It does not constitute investment advice.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MAGS ETF has retreated nearly 7% from its yearly high, with Meta and Tesla's financial reports triggering volatility. Microsoft, Alphabet, and Amazon are about to release their earnings, and market attention is shifting from revenue to AI capital expenditures and free cash flow. Each of the three tech giants has invested over $100 billions in AI.

智通财经•2026/10/26 00:36